New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2013
08:20 EDTSLXPSalix subpoena unlikely to have material impact, says Wells Fargo
After Salix received a subpoena over sales and marketing practices for three of its drugs, Wells Fargo doesn't expect the subpoenas to have a significant impact on the company's underlying operations. The firm maintains an Outperform rating on the stock.
News For SLXP From The Last 14 Days
Check below for free stories on SLXP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
10:02 EDTSLXPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTSLXPDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:08 EDTSLXPSalix initiated with a Hold at Deutsche Bank
Subscribe for More Information
July 17, 2014
05:24 EDTSLXPSalix, Pharming Group announces FDA approval of Ruconest
Subscribe for More Information
July 16, 2014
09:12 EDTSLXPLeerink healthcare analyst holds an analyst/industry conference call
Subscribe for More Information
July 14, 2014
07:07 EDTSLXPFDA says RELISTOR can be approved on data submitted in sNDA
Salix Pharmaceuticals (SLXP) and Progenics Pharmaceuticals (PGNX) announced that the Food and Drug Administration has informed Salix that RELISTOR can be approved on the data submitted in the sNDA. The FDA Office of Drug Evaluation III responded to the company’s formal appeal filed in response to the Complete Response Letter of July 27, 2012 to the supplemental NDA ) for RELISTOR. The Agency’s letter stated that, “Salix’s request that FDA approve the supplemental NDA for RELISTOR subcutaneous injection for the treatment of opioid-induced constipation in patients with chronic non-cancer pain based on the submitted data is granted.” This request for a proposal for a post-marketing observational study is in accordance with recommendations of the June 11-12, 2014 meeting of the Anesthetic and Analgesic Drug Product Advisory Committee. Salix will work with the DGIEP in an effort to provide information to the division that will enable the division to approve RELISTOR for use by patients with chronic non-cancer pain and experiencing OIC.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use